TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the curve (AUC) (0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylation status of S6K and CA IX protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first requirement of analgesic supplement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to hormonal therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pure tone audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impedance audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Otoendoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External ear canal dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of acute diverticulitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients Delivered by Cesarean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Area of distribution of contrast dye in the intraperitoneal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of liver volume predicted by scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Weekly Complete Spontaneous Bowel Movement Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery of Bowel Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of events of prosthodontic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Dorilax® plus thermal band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Security of Dorilax® plus thermal band
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Calcitriol Plasma Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmin of Calcitriol Plasma Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC (0-6h) of Calcitriol Plasma Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urapidil consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of patients achieving myeloablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence and severity of AEs and SAEs, including changes in laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Change of E2 [mg/l]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of LH [mg/l]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Prog [mg/l]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity of Alopecia Tool (SALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment response evaluated by PERCIST to RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy Root Mean Square (ARMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Left ventricular mass (LVM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants who experienced an adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who experienced a serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who experienced a Grade 1-4 laboratory abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)
Endpoint domain: Physiological/clinical
Primary endpoint: APACHE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of Confabulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the number of correct responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the number of non-responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Treatment response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: anxiety for anomalies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anxiety for stillbirths
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anxiety for preterm labour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibody titer serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infiltration scale for infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phlebitis Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of final vascular anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Efficacy of olanzapine in treating mania
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Depression Inventory-II Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttraumatic Distress Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: short-term surgical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of total necrotic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life score in the Minnesota living with heart failure questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mortality after TAVI
Endpoint domain: Mortality/survival
Primary endpoint: Number of Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Discontinued Opioids by 3 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical response (closure of perianal fistulas)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre- and post-bronchodilator FEV1 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of retear
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteraemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Red blood cells (RBC) concentration of 6-mercaptopurine (6-MP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in blood pressure from supine to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional activity measurement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of subcutaneous injections of tumor associated antigens
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting One or More Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting One or More Serious Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of SNPs associated with prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ordinal Modified Rankin Scale (mRS) Score at Day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Response Rate (ORR) Based on Independent Review-Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) Based on Independent Review-Part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) Based on Investigator Assessment-Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) Based on Investigator Assessment-Part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta-LVEF at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proteomic level evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MRD negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in 24hr mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Current Study Baseline in Total Bone Marrow Burden (BMB) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Current Study Baseline in Total Spine and Femur Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of New or Worsening Fracture Events for Spine and Femur
Endpoint domain: Adverse events/effects
Primary endpoint: Pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient overall health assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recruitment (acceptability of the trial by trainees)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of recruitment (acceptability of the trial by attending surgeons)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of missing assessment data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-surgical Resolution of Focal VMT/sVMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of Lipiodol demarcation on planning CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of Lipiodol on CBCT during Radiotherapy treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Covid-19 related psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of subjects in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC0-tz of midazolam and omeprazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of midazolam and omeprazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-specific skills acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Non-suicidal self-injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum depression assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion of Clinical Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of Assigned Monitoring
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time on Ventilatory Support Required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Supplemental Oxygen Need
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Aβ and t-tau changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma inflammatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma metabolic changes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with tumor antigen expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cure rate of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Denovo urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of radiographic damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Myelin water fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Western Ontario and McMaster Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Douleur Neuropathique 4 Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intubation and mechanical ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in 1 Second (FEV1) AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in hepatic fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transcriptional signature of Major Depressive Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In hospital death
Endpoint domain: Mortality/survival
Primary endpoint: Latency to Sleep Onset on Maintenance of Wakefulness Test (MWT)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Spontaneous Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants to Whom an AAP Was Delivered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Identification recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival free of pump malfunction due to thrombosis or ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in colony forming units (CFUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in metabolic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to progression or death
Endpoint domain: Mortality/survival
Primary endpoint: Number of required dose adjustments of Tacrolimus formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of HAMD17 total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Cultivable Bacterial Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Alveolar Crestal Bone Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success (re-intervention required)
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Best response related to brain metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with chronic refractory dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Retinal and vascular features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Difference in VAS (Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of Beta-2-microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes to Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptomatic Laboratory-confirmed COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptomatic Laboratory-confirmed VRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Achieve Remission of Arthritis and/or Rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of COVID-19 Exposed Individuals With a Positive COVID-19 Test
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Clinical Benefit at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Expression Recognition Task (FERT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Verbal Learning Task (AVLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Survival with a functional graft
Endpoint domain: Mortality/survival
Primary endpoint: COVID-19 case status
Endpoint domain: Mortality/survival
Primary endpoint: AUC of radium-223 in tumor-free bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) as determined by number of participants with dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients correctly identified by recurrence predictive model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first ICD shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Leg, neck and total body fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Post-Operative Nausea and Vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Are Alive at 42 Days After Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Microneurography (MSNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vein size with MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of any grade 4 or greater suspected adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Vomiting and Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Enrollment rate in CAR-T study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunosuppression damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stone clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor stage of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resectability rate of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in Endothelial Progenitor Cells (CD34+KDR+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulins A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infant Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Gestational Age at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APGAR Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Chronic Pain in Older People (CPOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maternal mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence/severity of postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in physical fitness pre - post
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in physical activity pre - post
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in well-being pre - post
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients Achieving Complete Control (CC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes